Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Clostridium difficile infection? 141 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 141 reports of Clostridium difficile infection have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.1% of all adverse event reports for TOCILIZUMAB.

141
Reports of Clostridium difficile infection with TOCILIZUMAB
0.1%
of all TOCILIZUMAB reports
4
Deaths
97
Hospitalizations

How Dangerous Is Clostridium difficile infection From TOCILIZUMAB?

Of the 141 reports, 4 (2.8%) resulted in death, 97 (68.8%) required hospitalization, and 3 (2.1%) were considered life-threatening.

Is Clostridium difficile infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 141 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Clostridium difficile infection?

ADALIMUMAB (1,502) INFLIXIMAB (1,419) VEDOLIZUMAB (1,130) LENALIDOMIDE (814) VANCOMYCIN (743) METRONIDAZOLE (619) PREDNISONE (618) METHOTREXATE (588) RITUXIMAB (532) CIPROFLOXACIN (508)

Which TOCILIZUMAB Alternatives Have Lower Clostridium difficile infection Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Clostridium difficile infection Reports All Drugs Causing Clostridium difficile infection TOCILIZUMAB Demographics